It is assumed that the miR-34c-5p/SIRT6/JAK2/STAT3 axis could be an innovative therapeutic target that opens new insights into developing treatment approaches for colon cancer therapy [80]. This evidence concerns the gene STAT3 and malignant colon neoplasm.